PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Danger in disguise: UCLA researchers find brain cancer cells can 'hide' from drugs

2013-12-11
(Press-News.org) Contact information: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Danger in disguise: UCLA researchers find brain cancer cells can 'hide' from drugs Researchers from UCLA's Jonsson Comprehensive Cancer Center have discovered a biological mechanism that makes brain tumor cells drug resistant by allowing them to escape from the drugs designed to target them. The study was published online Dec. 5 by the journal Science.

Glioblastoma is the most common and deadliest form of brain cancer, and the surface of its cells are marked by telltale mutations that accelerate tumor growth. The drugs currently used to find and kill glioblastoma cells target those mutations.

Led by first author David Nathanson, assistant professor of molecular and medical pharmacology at UCLA, and former UCLA professor Paul Mischel, now at the Ludwig Institute for Cancer Research at UC San Diego, the researchers found that the tumor cells temporarily eliminate the gene mutation when they sense the presence of the cancer drug, essentially removing the drug's target and allowing the tumor to become drug resistant.

Remarkably, the study also found that after the drug is removed, the tumor cells reacquire the gene mutation (called an oncogene) that helps the tumor cells grow more robustly, and that they can repeat this cycle as often as the drug is given. Importantly, that ability is what could make the cancer cells vulnerable to the original therapy: Doctors may be able to use pulsative drug delivery, for example, to take better advantage of the periods when the cancer cells are sensitized to the drugs.

"Now that we know that tumor cells have the surprising capacity to lose this oncogene during treatment and then reverse the process after drug removal, we may be able to exploit this phenomenon in the clinic," Nathanson said.

Co-authors of the study included Jonsson Cancer Center professors Harley Kornblum and James Heath (who also has an appointment at the California Institute of Technology) in collaboration with UCLA's Dr. Timothy Cloughesy and Nagesh Rao.

This is the first study to show reversible loss of an oncogene causing drug resistance, and it could hold promise for the treatment of other cancers susceptible to oncogene elimination, such as certain types of breast cancer.

INFORMATION:

This research was supported by the Ben and Catherine Ivy Foundation fund, the National Institutes of Health, the Ziering Family Foundation, the Art of the Brain fund, the James S. McDonnell Foundation, the European Commission, the Ruth L. Kirschstein Institutional National Research Service Award, the UCLA Scholars in Oncologic Molecular Imaging program and the Ludwig Institute for Cancer Research.

UCLA's Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2013, the Jonsson Cancer Center was named among the top 12 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 14 consecutive years.

For more news, visit the UCLA Newsroom and follow us on Twitter.

END



ELSE PRESS RELEASES FROM THIS DATE:

New study shows a breadth of antisense drug activity across many different organs

2013-12-11
New study shows a breadth of antisense drug activity across many different organs New Rochelle, NY, December 10, 2013—Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional ...

Exercise alleviates sexual side-effects of antidepressants in women, study shows

2013-12-11
Exercise alleviates sexual side-effects of antidepressants in women, study shows Findings could lead to new treatment for sexual dysfuntion in women taking antidepressants AUSTIN, Texas – New psychology research, which could have important public health implications ...

Malnourished children still have hope beyond first 1,000 days

2013-12-11
Malnourished children still have hope beyond first 1,000 days BYU research shows early developmental damage can be reversed Children who are malnourished during their first 1000 days (conception to age 2) often experience developmental setbacks that affect them for ...

Early initiation of ER palliative care consultations resulted in shorter hospital stays

2013-12-11
Early initiation of ER palliative care consultations resulted in shorter hospital stays The results indicate that Accountable Care Organizations could be spending health care dollars more wisely, thus sharing in the savings it achieves for the Medicare program New ...

NREL reports soft costs now largest piece of solar installation total cost

2013-12-11
NREL reports soft costs now largest piece of solar installation total cost Two detailed reports from the Energy Department's National Renewable Energy Laboratory (NREL) find that solar financing and other non-hardware costs — often referred ...

Food and Chemical Toxicology Editor-in-Chief, A. Wallace Hayes, publishes response to letters to the editor

2013-12-11
Food and Chemical Toxicology Editor-in-Chief, A. Wallace Hayes, publishes response to letters to the editor Cambridge, MA, December 10, 2013 – The following statement will be published in the journal, Food and Chemical Toxicology, alongside a selection of letters to the ...

NASA: Fire vs. ice: The science of ISON at perihelion

2013-12-11
NASA: Fire vs. ice: The science of ISON at perihelion After a year of observations, scientists waited with bated breath on Nov. 28, 2013, as Comet ISON made its closest approach to the sun, known as perihelion. Would the comet disintegrate in ...

Researchers to present event-free and overall survival results from NeoALTTO trial

2013-12-11
Researchers to present event-free and overall survival results from NeoALTTO trial SAN ANTONIO — Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or ...

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab

2013-12-11
High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab SAN ANTONIO — Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from ...

Study identifies highly effective treatment option for patients with HER2-positive breast cancer

2013-12-11
Study identifies highly effective treatment option for patients with HER2-positive breast cancer SAN ANTONIO — Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal ...

LAST 30 PRESS RELEASES:

People with schizophrenia have higher risk of COPD

Sibling-specific aggression in women and girls

Study raises red flags about BPA replacements

The irresistibility of extrapolating from past performance

Predicting nationality from beliefs and values

Mindset shift about catastrophes linked to decreased depression, inflammation

Astronomers make unexpected discovery of planet in formation around a young star

EBMT partners in a new consortium to decentralise CAR-T cell therapy and improve hospital workflow

Primate thumbs and brains evolved hand-in-hand

Sneaky swirls: scientists confirm ‘hidden’ vortices could influence how soil and snow move

Tropical volcanic eruptions push rainfall across the equator

UCLA scientists map primate ovarian reserve development, offering key insights into women’s health

BU study finds type 2 diabetes blood factors drive breast cancer aggression

AI chatbots inconsistent in answering questions about suicide

More efficient and reliable SiC devices for a greener future

Two thirds of reproductive-aged women have at least one modifiable risk factor for birth defects, study reveals

Boosting the neuroglia as a therapeutic strategy for brain disorders

Computational neurogenomics revolution unlocks personalized treatments for brain disorders worldwide

Psychedelics researcher reveals how MDMA and LSD transform human connectedness

Making low-fertility rats fertile by changing the treatment interval

Common painkillers linked to antibiotic resistance

Teachers' depression, anxiety and stress at three times the national norm: new study

Common cold may protect against COVID-19 according to National Jewish Health researchers

New project to improve information retrieval for lifelong learning

New method probes cancer cell messengers that weaken immune system

VCs backed Black founders after BLM – but it didn’t last

A new tool to track infant development, starting at just 16 days old

Generative AI uncovers undetected bird flu exposure risks in Maryland emergency departments

High concentration THC associated with schizophrenia, psychosis, and other unfavorable mental health outcomes

Mediterranean diet with fewer calories and exercise lowers diabetes risk by 31%

[Press-News.org] Danger in disguise: UCLA researchers find brain cancer cells can 'hide' from drugs